

ARISTADA - (441MG/1.6ML, 662MG/2.4ML, 882MG/3.2ML, 1064MG/3.9ML ; SUSPENSION,EXTENDED RELEASE)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | ARIPIRAZOLE LAUROXIL | Innovator | Alkermes |
| Dosage | 441MG/1.6ML, 662MG/2.4ML, 882MG/3.2ML, 1064MG/3.9ML ; SUSPENSION,EXTENDED RELEASE | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | ARISTADA is an atypical antipsychotic indicated for the treatment of schizophrenia. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.